APA (7th ed.) Citation

Yang, G., Ma, D., Xu, H., Yang, L., Li, J., Xing, P., . . . Wang, Y. (2019). Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study. Wiley.

Chicago Style (17th ed.) Citation

Yang, Guangjian, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, and Yan Wang. Treatment Duration as a Surrogate Endpoint to Evaluate the Efficacy of Crizotinib in Sequential Therapy for Patients with Advanced ALK‐positive Non‐small Cell Lung Cancer: A Retrospective, Real‐world Study. Wiley, 2019.

MLA (9th ed.) Citation

Yang, Guangjian, et al. Treatment Duration as a Surrogate Endpoint to Evaluate the Efficacy of Crizotinib in Sequential Therapy for Patients with Advanced ALK‐positive Non‐small Cell Lung Cancer: A Retrospective, Real‐world Study. Wiley, 2019.